Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models
- PMID: 15578690
- DOI: 10.1002/gcc.20118
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models
Abstract
Tuberous sclerosis complex (TSC) is a familial tumor disorder for which there is no effective medical therapy. Disease-causing mutations in the TSC1 or TSC2 gene lead to increased mammalian target of rapamycin (mTOR) kinase activity in the conserved mTOR signaling pathway, which regulates nutrient uptake, cell growth, and protein translation. The normal function of TSC1 and TSC2 gene products is to form a complex that reduces mTOR kinase activity. Thus, mTOR kinase inhibition may be a useful targeted therapeutic approach. Elevated interferon-gamma (IFN-gamma) expression is associated with decreased severity of kidney tumors in TSC patients and mouse models; therefore, IFN-gamma also has therapeutic potential. We studied cohorts of Tsc2+/- mice and a novel mouse model of Tsc2-null tumors in order to evaluate the efficacy of targeted therapy for TSC. We found that treatment with either an mTOR kinase inhibitor (CCI-779, a rapamycin analog) or with IFN-gamma reduced the severity of TSC-related disease without significant toxicity. These results constitute definitive preclinical data that justify proceeding with clinical trials using these agents in selected patients with TSC and related disorders.
Similar articles
-
Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.Genes Chromosomes Cancer. 2006 Oct;45(10):933-44. doi: 10.1002/gcc.20357. Genes Chromosomes Cancer. 2006. PMID: 16845661
-
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.Cancer Res. 2002 Oct 15;62(20):5645-50. Cancer Res. 2002. PMID: 12384518
-
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.BMC Pharmacol. 2007 Nov 6;7:14. doi: 10.1186/1471-2210-7-14. BMC Pharmacol. 2007. PMID: 17986349 Free PMC article.
-
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. doi: 10.1093/hmg/ddi260. Hum Mol Genet. 2005. PMID: 16244323 Review.
-
The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review.
Cited by
-
Rapamycin and rapalogs for tuberous sclerosis complex.Cochrane Database Syst Rev. 2023 Jul 11;7(7):CD011272. doi: 10.1002/14651858.CD011272.pub3. Cochrane Database Syst Rev. 2023. PMID: 37432030 Free PMC article. Review.
-
Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.JCI Insight. 2023 May 8;8(9):e166850. doi: 10.1172/jci.insight.166850. JCI Insight. 2023. PMID: 36927688 Free PMC article.
-
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion.Nat Commun. 2023 Mar 3;14(1):1214. doi: 10.1038/s41467-023-36881-7. Nat Commun. 2023. PMID: 36869048 Free PMC article.
-
Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex.Front Oncol. 2022 Jun 23;12:851192. doi: 10.3389/fonc.2022.851192. eCollection 2022. Front Oncol. 2022. PMID: 35814396 Free PMC article.
-
eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest.Int J Mol Sci. 2022 Jun 22;23(13):6932. doi: 10.3390/ijms23136932. Int J Mol Sci. 2022. PMID: 35805935 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous